Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, given as 2 tablets of 5mg/1000mg.
Patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy:
When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse effects of metformin.
For patients switching from concomitant dapagliflozin and metformin therapy to this medicine, the dose of this medicine may be initiated at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately.
The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because such a change may result in changes in glycemic control, any change in treatment in patients with type 2 diabetes should be made under close monitoring.
This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet.
Renal impairment
No dose adjustment is required for patients with mild renal impairment.
For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or greater and less than 60 mL/min/1.73 m2, who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2.
If the eGFR falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
Older adults
Metformin is excreted by the kidneys, and older adults are more likely to have decreased renal function; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults).
Improvement of glycemic control in adults with type 2 diabetes mellitus
Inadequate blood sugar control
type 2 diabetes
cardiovascular disease
cardiovascular risk factors
View approved original textHide original text
This medication is used to improve blood sugar control in adult patients with type 2 diabetes when administered in conjunction with dietary and exercise therapy. It can be used particularly in patients who have cardiovascular disease or cardiovascular risk factors and are not adequately controlled. It is important to refer to an expert's guidelines regarding the risk of cardiovascular events during the treatment process. This medication assists in managing blood sugar levels during diabetes treatment.
How to take
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, given as 2 tablets of 5mg/1000mg.
Patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy:
When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse effects of metformin.
For patients switching from concomitant dapagliflozin and metformin therapy to this medicine, the dose of this medicine may be initiated at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately.
The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because such a change may result in changes in glycemic control, any change in treatment in patients with type 2 diabetes should be made under close monitoring.
This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet.
Renal impairment
No dose adjustment is required for patients with mild renal impairment.
For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or greater and less than 60 mL/min/1.73 m2, who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2.
If the eGFR falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
Older adults
Metformin is excreted by the kidneys, and older adults are more likely to have decreased renal function; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults).
Precautions
This medication is used for diabetes treatment and should not be administered to patients with impaired kidney function or those suffering from certain acute illnesses.
This medication can rarely cause a severe side effect known as lactic acidosis, so it is essential to be aware of the symptoms or risk factors associated with lactic acidosis.
When used alongside other hypoglycemic agents such as insulin or sulfonylureas, hypoglycemia may occur, so careful monitoring of blood sugar levels is necessary.
Use with caution in patients with reduced fluid volume or low blood pressure, elderly patients, and those with compromised kidney function; kidney function and blood pressure should be thoroughly checked before and after administration.
This medication may increase the risk of genital and urinary tract infections, so if any infection symptoms arise, seek medical advice immediately.
Women who are pregnant or breastfeeding should not use this medication, and women of childbearing potential should consult a healthcare professional before taking this medication.
During the course of this medication, excessive alcohol consumption should be avoided, as alcohol may increase the risk of side effects.
Vitamin B12 deficiency may occur, so regular monitoring of blood levels of vitamin B12 is advised for long-term use.
This medication may cause dizziness when driving or operating machinery, so caution is needed.
This medication should be kept out of the reach of children and stored in its original container to prevent degradation or misuse.
Side effects
Severe lactic acidosis
severe hypoglycemia
vulvovaginitis
balanitis
genital infection
urinary tract infection
fungal infection
hypoglycemia
decreased fluid volume
thirst
Show 84 moreCollapse
diabetic ketoacidosis
dizziness
constipation
dry mouth
back pain
dysuria
polyuria
nocturia
pruritus of the vulva
pruritus of the genitals
elevated hematocrit
decreased renal creatinine clearance
dyslipidemia
elevated serum creatinine
elevated blood urea
weight loss
ketoacidosis
urosepsis
pyelonephritis
acute kidney injury
renal dysfunction
rash
diarrhea
nausea
vomiting
decreased vitamin B12
Guillain-Barré syndrome
bacterial pneumonia
sialadenitis
tendinitis
chest pain
thermal burns
wrist fractures
gastrointestinal stromal tumors
lung malignancies
uterine fibroids
atrial fibrillation
acute cholecystitis
upper abdominal pain
dyspepsia
abdominal discomfort
abdominal pain
gastric ulcers
irritable bowel syndrome
salivary gland masses
toothache
headache
facial paralysis
peripheral neuropathy
sensory disturbances
drowsiness
tremor
nasopharyngitis
pharyngitis
adenoviral conjunctivitis
shingles
pneumonia
rhinitis
increased alanine aminotransferase
elevated blood sugar
arthralgia
myalgia
myofascial pain syndrome
osteoarthritis
osteochondrosis
limb pain
periartritis
tendinosis
trigger finger
weakness
fatigue
peripheral edema
swelling
pain
vitamin D deficiency
hyperglycemia
urethral syndrome
cough
hyperventilation
itching
palpitations
insomnia
type 2a hyperlipidemia
sensorineural hearing loss
Not everyone experiences these, and they can vary from person to person.
Storage
This medication may be sensitive to air or moisture, so it should be stored in a sealed container. The storage temperature should be kept at room temperature, between 1 and 30 degrees Celsius. This helps maintain the medication's effectiveness and safety over time.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.